This is definitely an over reaction
the trial results were completely consistent to what had been seen in the earlier trials - the drug works well (statistically and clinically significant) in sick patients.
This is the first time less sick patients were tested with the drug, and they were found to not benefit like the sicker patients do
this is valuable new info. Now dxb knows their optimal patient group for future studies
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-164
-
- There are more pages in this discussion • 464 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
49.5¢ |
Change
0.020(4.21%) |
Mkt cap ! $261.3M | |||
| Open | High | Low | Value | Volume |
| 47.5¢ | 50.0¢ | 47.5¢ | $412.8K | 847.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 131961 | 49.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 50.0¢ | 170569 | 7 |
View Market Depth
| Last trade - 10.38am 16/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |